Edgewise Therapeutics, Inc., a leading muscle disease biopharmaceutical company, announced the dosing of the first patient in the phase 2 CIRRUS-HCM trial of EDG-7500. EDG-7500 is a novel oral, ...
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy ...
EXPLORER-HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation Mavacamten Treatment Resulted in Favorable Effect on Cardiac Structure -- ...
When a young athlete suddenly dies of a heart attack, chances are high that they suffer from familial hypertrophic cardiomyopathy (HCM). Itis the most common genetic heart disease in the US and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback